149 related articles for article (PubMed ID: 25541467)
1. Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1.
Hintzpeter J; Hornung J; Ebert B; Martin HJ; Maser E
Chem Biol Interact; 2015 Jun; 234():162-8. PubMed ID: 25541467
[TBL] [Abstract][Full Text] [Related]
2. Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
Pirolli D; Giardina B; Mordente A; Ficarra S; De Rosa MC
Eur J Med Chem; 2012 Oct; 56():145-54. PubMed ID: 22982121
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.
Ferguson DC; Cheng Q; Blanco JG
Drug Metab Dispos; 2015 Jul; 43(7):922-7. PubMed ID: 25918240
[TBL] [Abstract][Full Text] [Related]
4. Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma.
Huang W; Ding L; Huang Q; Hu H; Liu S; Yang X; Hu X; Dang Y; Shen S; Li J; Ji X; Jiang S; Liu JO; Yu L
Hepatology; 2010 Aug; 52(2):703-14. PubMed ID: 20683966
[TBL] [Abstract][Full Text] [Related]
5. Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.
Quiñones-Lombraña A; Ferguson D; Hageman Blair R; Kalabus JL; Redzematovic A; Blanco JG
Pharm Res; 2014 Jul; 31(7):1644-55. PubMed ID: 24562808
[TBL] [Abstract][Full Text] [Related]
6. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.
Gonzalez-Covarrubias V; Ghosh D; Lakhman SS; Pendyala L; Blanco JG
Drug Metab Dispos; 2007 Jun; 35(6):973-80. PubMed ID: 17344335
[TBL] [Abstract][Full Text] [Related]
7. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes.
Plebuch M; Soldan M; Hungerer C; Koch L; Maser E
Cancer Lett; 2007 Sep; 255(1):49-56. PubMed ID: 17482758
[TBL] [Abstract][Full Text] [Related]
8. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
9. The modulation of carbonyl reductase 1 by polyphenols.
Boušová I; Skálová L; Souček P; Matoušková P
Drug Metab Rev; 2015; 47(4):520-33. PubMed ID: 26415702
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of human carbonyl reductase 1 (CBR1) by the prenylated chalconoid xanthohumol and its related prenylflavonoids isoxanthohumol and 8-prenylnaringenin.
Seliger JM; Martin HJ; Maser E; Hintzpeter J
Chem Biol Interact; 2019 May; 305():156-162. PubMed ID: 30849340
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship of flavonoids as potent inhibitors of carbonyl reductase 1 (CBR1).
Arai Y; Endo S; Miyagi N; Abe N; Miura T; Nishinaka T; Terada T; Oyama M; Goda H; El-Kabbani O; Hara A; Matsunaga T; Ikari A
Fitoterapia; 2015 Mar; 101():51-6. PubMed ID: 25549925
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation of the canine carbonyl reductase 1 gene (cbr1) by the specificity protein 1 (Sp1).
Quiñones-Lombraña A; Cheng Q; Ferguson DC; Blanco JG
Gene; 2016 Oct; 592(1):209-214. PubMed ID: 27506315
[TBL] [Abstract][Full Text] [Related]
13. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
Jamrozik M; Piska K; Bucki A; Koczurkiewicz-Adamczyk P; Sapa M; Władyka B; Pękala E; Kołaczkowski M
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175180
[TBL] [Abstract][Full Text] [Related]
14. Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin.
Sheng X; Parmentier JH; Tucci J; Pei H; Cortez-Toledo O; Dieli-Conwright CM; Oberley MJ; Neely M; Orgel E; Louie SG; Mittelman SD
Mol Cancer Res; 2017 Dec; 15(12):1704-1713. PubMed ID: 29117945
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance.
Hintzpeter J; Seliger JM; Hofman J; Martin HJ; Wsol V; Maser E
Toxicol Appl Pharmacol; 2016 Feb; 293():21-9. PubMed ID: 26773812
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1.
Hu D; Miyagi N; Arai Y; Oguri H; Miura T; Nishinaka T; Terada T; Gouda H; El-Kabbani O; Xia S; Toyooka N; Hara A; Matsunaga T; Ikari A; Endo S
Org Biomol Chem; 2015 Jul; 13(27):7487-99. PubMed ID: 26068795
[TBL] [Abstract][Full Text] [Related]
17. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Varatharajan S; Abraham A; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Eur J Clin Pharmacol; 2012 Dec; 68(12):1577-86. PubMed ID: 22562609
[TBL] [Abstract][Full Text] [Related]
18. Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?
Novotná E; Morell A; Büküm N; Hofman J; Danielisová P; Wsól V
Arch Toxicol; 2020 Sep; 94(9):3059-3068. PubMed ID: 32588086
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).
Gonzalez-Covarrubias V; Kalabus JL; Blanco JG
Pharm Res; 2008 Jul; 25(7):1730-4. PubMed ID: 18449627
[TBL] [Abstract][Full Text] [Related]
20. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
